Kornitzer Capital Management Inc. KS Sells 388 Shares of Illumina, Inc. (NASDAQ:ILMN)

Kornitzer Capital Management Inc. KS decreased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 20,664 shares of the life sciences company’s stock after selling 388 shares during the quarter. Kornitzer Capital Management Inc. KS’s holdings in Illumina were worth $2,761,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Bleakley Financial Group LLC bought a new position in shares of Illumina during the 4th quarter worth $751,000. Zacks Investment Management bought a new position in shares of Illumina during the 3rd quarter worth $2,924,000. Van ECK Associates Corp grew its position in shares of Illumina by 17.5% during the 4th quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company’s stock worth $20,347,000 after buying an additional 22,718 shares in the last quarter. Freemont Management S.A. bought a new position in shares of Illumina during the 3rd quarter worth $1,565,000. Finally, Assenagon Asset Management S.A. boosted its position in Illumina by 5.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 42,748 shares of the life sciences company’s stock valued at $5,712,000 after purchasing an additional 2,338 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Trading Up 0.8 %

Illumina stock opened at $101.05 on Wednesday. Illumina, Inc. has a 52 week low of $99.33 and a 52 week high of $156.66. The company has a market capitalization of $16.03 billion, a price-to-earnings ratio of -13.16 and a beta of 1.10. The stock has a 50-day moving average price of $130.85 and a 200 day moving average price of $134.63. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 12.59%. Sell-side analysts anticipate that Illumina, Inc. will post 4.42 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on ILMN. UBS Group raised their price objective on Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Stephens raised their price objective on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research report on Tuesday, November 12th. Robert W. Baird raised their price objective on Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a research report on Wednesday, November 6th. Citigroup downgraded Illumina from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $190.00 to $165.00 in a research report on Wednesday, December 11th. Finally, Royal Bank of Canada dropped their price objective on Illumina from $250.00 to $247.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Illumina currently has an average rating of “Moderate Buy” and an average price target of $159.45.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.